Compare Neurocrine Biosciences Inc (NBIX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs DENTSPLY SIRONA Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while DENTSPLY SIRONA Inc trades at $10.7 (market cap $2.19B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | XRAY | |
|---|---|---|
Market Cap | $15.77B | $2.19B |
Sector | Health | Health |
52-Week High | $185.50 | $14.68 |
52-Week Low | $123.10 | $9.64 |
Enterprise Value | $15.78B | $4.26B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing pressure from declining revenues and negative profitability. The stock shows a bearish technical signal, with key support at $10. Recent Q2 2026 earnings beat estimates but sales fell 4.1%, highlighting persistent challenges in dental markets. Cash flow improved in 2025, yet net losses and high debt levels remain concerns.
The outlook is cautious; while analyst consensus suggests modest upside to a $12.50 target, weak margins, falling sales, and potential fiduciary scrutiny pose significant risks. Recovery depends on successful execution of the company's turnaround plan amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
